4503 Stock Overview
Manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
Astellas Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥1,513.50 |
52 Week High | JP¥2,360.50 |
52 Week Low | JP¥1,426.00 |
Beta | 0.31 |
1 Month Change | 4.27% |
3 Month Change | -9.64% |
1 Year Change | -32.54% |
3 Year Change | -10.34% |
5 Year Change | 0.033% |
Change since IPO | 157.40% |
Recent News & Updates
Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear
May 02Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 29Shareholder Returns
4503 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | -1.8% | 1.6% | 0.6% |
1Y | -32.5% | 5.3% | 24.2% |
Return vs Industry: 4503 underperformed the JP Pharmaceuticals industry which returned 5.2% over the past year.
Return vs Market: 4503 underperformed the JP Market which returned 25.1% over the past year.
Price Volatility
4503 volatility | |
---|---|
4503 Average Weekly Movement | 3.6% |
Pharmaceuticals Industry Average Movement | 3.8% |
Market Average Movement | 4.1% |
10% most volatile stocks in JP Market | 8.1% |
10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4503 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4503's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1923 | 14,484 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Astellas Pharma Inc. Fundamentals Summary
4503 fundamental statistics | |
---|---|
Market cap | JP¥2.71t |
Earnings (TTM) | JP¥17.05b |
Revenue (TTM) | JP¥1.60t |
159.2x
P/E Ratio1.7x
P/S RatioIs 4503 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4503 income statement (TTM) | |
---|---|
Revenue | JP¥1.60t |
Cost of Revenue | JP¥292.49b |
Gross Profit | JP¥1.31t |
Other Expenses | JP¥1.29t |
Earnings | JP¥17.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 9.51 |
Gross Margin | 81.76% |
Net Profit Margin | 1.06% |
Debt/Equity Ratio | 57.6% |
How did 4503 perform over the long term?
See historical performance and comparison